Highlights From Bruton’s Tyrosine Kinase Inhibitors: Updates and Advancements in the Treatment and Management of CLL/SLL
Highlights From Bruton’s Tyrosine Kinase Inhibitors: Updates and Advancements in the Treatment and Management of CLL/SLL is organized by Healthcare Made Practical (HMP) Global.
Release Date: July 12, 2023
Expiration Date: July 12, 2024.
Description:
This on-demand webcast is available with synchronized slides and video/audio. If you claimed credit for the live program held on June 5, 2023 in Chicago, Illinois, you are not eligible to claim credit for this enduring activity.
To be eligible for credit, participants must complete the educational activity, and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Learning Objectives:
After participating in this activity, learners should be better able to:
• Evaluate the efficacy of new and emerging targeted agents beyond the current chemotherapy standard for the treatment and management of CLL/SLL
• Assess the most current real-world clinical data including long-term patient outcomes data for fixed-duration treatments with Bruton’s tyrosine kinase (BTK) inhibitors alone and in combination with other targeted drugs for the treatment of CLL/SLL
• Implement appropriate treatment and management plans utilizing current clinical trial data in patients that have become refractory or resistant to prior CLL/SLL treatment strategies
• Evaluate the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with BTK inhibitors.
Additional details will be posted as soon as information is available.